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Association of G6PD202A,376G with lower haemoglobin
concentration but not increased haemolysis in patients with
sickle cell anaemia
Individuals with sickle cell anaemia, i.e., homozygotes for
the haemoglobin S mutation, have variability in the severity
of anaemia and degree of haemolysis at steady state
(Steinberg & Hebbel, 1983), and the reasons for this
variability are not fully known (Christakis et al, 1990).
a-Thalassaemia due to single or double HBA1/2 deletions
(Embury et al, 1982; Higgs et al, 1982; Chaar et al, 2006)
and higher haemoglobin F (Hb F) percentages (Serjeant,
1975; Maude et al, 1987; Franco et al, 2006) are associated
with higher haemoglobin concentrations and less haemolysis
in this setting.
The glucose-6-phosphate dehydrogenase (G6PD) gene
(G6PD) is located on the X chromosome. The normal allele is
termed G6PD B. Mild G6PD deficiency (G6PD A)) has a
prevalence of about 10% in predominantly African-American
United States sickle cell disease patients based on reduced
enzyme activity (Steinberg et al, 2003). The G6PD A) pheno-
type is usually caused by hemizygosity for both the G6PD202A
and G6PD376G alleles in males and homozygosity for both of
these alleles in females (Hirono & Beutler, 1988) and is referred
to as G6PD202A,376G in this report. Hemizygosity for G6PD376G
but not G6PD202A is termed G6PD A and is usually associated
with normal enzymatic activity. G6PD202A,376G has a prevalence
of about 12–13% in males and 2–3% in females in sub-Saharan
Africa (Guindo et al, 2007; Johnson et al, 2009) and accounts
for most of the G6PD deficiency in the population as
determined by enzymatic assay (Johnson et al, 2009). Other
genotypes, particularly inheritance of both the G6PD376G and
G6PD968C alleles (G6PD376G,968C), may contribute to the G6PD
A) phenotype and even predominate over G6PD202A,376G,
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Summary
The genetic bases of the highly variable degrees of anaemia and haemolysis in
persons with Hb SS are not fully known, but several studies have indicated
that G6PD deficiency is not a factor. The G6PD202A and G6PD376G alleles and
a-thalassaemia were determined by molecular genetic testing in 261 children
and adolescents with Hb SS in a multicentre study. G6PD202A,376G (G6PD
A)) was defined as hemizygosity for both alleles in males and homozygosity
in females. Among the participants 41% were receiving hydroxycarbamide.
The prevalence of G6PD202A,376G was 13Æ6% in males and 3Æ3% in females
with an overall prevalence of 8Æ7%. G6PD202A,376G was associated with a 10 g/l
decrease in haemoglobin concentration (P = 0Æ008) but not with increased
haemolysis as measured by lactate dehydrogenase, bilirubin, aspartate-
aminotransferase, reticulocyte count or a haemolytic component derived
from these markers (P > 0Æ09). Similar results were found within a sub-group
of children who were not receiving hydroxycarbamide. By comparison, single
and double a-globin deletions were associated with progressively higher
haemoglobin concentrations (P = 0Æ005 for trend), progressively lower values
for haemolytic component (P = 0Æ007), and increased severe pain episodes
(P < 0Æ001). In conclusion, G6PD202A,376G may be associated with lower
haemoglobin concentration in sickle cell anaemia by a mechanism other than
increased haemolysis.
Keywords: sickle cell anaemia, G6PD, haemolysis, alpha-thalassaemia, hae-
moglobin concentration.
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especially in certain parts of West Africa (De Araujo et al, 2006;
Clark et al, 2009).
G6PD A) may be associated with episodic haemolysis in
individuals of African descent and has a frequency among
sickle cell anaemia patients that is similar to the general
background population (Bienzle et al, 1975; Las Heras Manso
et al, 2008; Segeja et al, 2008). Little influence of G6PD A) on
the degree of anaemia and of haemolysis was reported in
several series of sickle cell anaemia patients (Gibbs et al, 1980;
Steinberg et al, 1988; Bernaudin et al, 2008). Here we
examined the effect of G6PD202A,376G, as determined by
molecular genetic testing, on the haemoglobin concentration
and degree of haemolysis in a cohort of children and
adolescents with haemoglobin SS (Hb SS) at steady state,
those enrolled in the Pulmonary Hypertension and the
Hypoxic Response in sickle cell disease (PUSH) Study
(Minniti et al, 2009).
Material and methods
Clinical study of participants
Individuals 3–20 years of age with sickle cell anaemia (Hb SS)
were recruited at three tertiary medical centres: Children’s
National Medical Center and Howard University Hospital in
Washington, DC, and University of Michigan in Ann Arbor,
Michigan. Children were recruited as outpatients when they
presented for routine, ongoing care. To ensure that patients
were enrolled at steady state, at least 3 weeks had to have
elapsed since hospitalization, emergency department visit, or
clinic visit for acute chest syndrome, pain crisis, infection or
other sickle cell disease-related complication. Written in-
formed consent was obtained for all participants. Parents or
legal guardians provided consent for children aged 3–17 years.
Participants aged 18–20 years provided consent for themselves.
Participants aged 7–17 years provided additional written
informed assent. Participants receiving regular blood transfu-
sions or hydroxycarbamide therapy were not excluded.
Detailed descriptions of experimental methods were published
recently (Gordeuk et al, 2009; Minniti et al, 2009).
Molecular genetic testing
G6PD. G6PD genotyping was conducted on a LightCycler480
(LC480) Real-Time PCR System (Roche Applied Science,
Indianapolis, IN) using TaqMan custom probes (Applied
Biosystems, Foster City, CA). In this report, G6PD202A,376G
indicates boys who are hemizygous and girls who are
homozygous for both the G6PD202A and the G6PD376G alleles
(Table I), and this genotype is strongly associated with
glucose-6-phosphate dehydrogenase deficiency (Hirono &
Beutler, 1988). HBB: Haemoglobin S genotyping was con-
ducted at ARUP Laboratories (Salt Lake City, UT) using loci-
spanning probe – PCR as described (Pont-Kingdon et al,
2007). HBA1/2: a-thalassaemia genotyping was performed as
described (Tan et al, 2001).
Echocardiography
Transthoracic echocardiography was performed using the
Philips Sono 5500/7500 or iE33, Acuson Sequoia, or General
Electric VIVID 7 or VIVID I instruments. Systolic pulmonary
artery pressure was estimated through measurement of tricus-
pid regurgitation velocity. Cardiac images were obtained,
measurements performed, and studies interpreted centrally
according to guidelines of the American Society of Echocar-
diography(Lai et al, 2006).
Statistical analysis
Principal component analysis of age-adjusted values for
lactate dehydrogenase (LDH), asparate aminotransferase
(AST), reticulocyte count and total bilirubin was used to
develop a haemolytic component that predicted 63% of
variability among these factors and had a mean of 0 and
standard deviation (SD) of 1Æ52. The arbitrary units of this
variable were converted to positive SD units with a mean of
3Æ0 and SD of 1Æ00. Principal component analysis is used
when the objective of the study is to investigate the role of an
underlying mechanism (Genser et al, 2007), in this case the
degree of haemolysis. The development of such a component
resolves the problem of dealing with correlated predictors in
multivariate analyses. Continuous and categorical variables
were examined according to different genotypes by linear test
for trend, student’s t test or Chi-square. Multiple linear
regression models were developed to identify the independent
predictors of haemoglobin concentration and haemolytic
component. These models were checked for model assump-
tions and outliers. An arbitrary level of 5% statistical
significance was assumed to be significant. Statistical analyses
were performed with stata 10Æ0 (StataCorp, College Station,
TX, USA).





202G,376A 68 Val,126 Asn G6PD B Normal
202G,376G 68 Val,126 Asp G6PD A Electrophoretic variant
with normal activity
202A,376G 68 Met,126 Asp G6PD A) Deficient variant
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Results
Demographics and genotypes
Two hundred and sixty-one Hb SS patients were studied for
G6PD202A,376G and for HBA1/2 deletions. The median age was
12 years, 47% were females, and 98% were African Americans.
The allele frequencies for G6PD376G (35Æ2%), G6PD202A
(19Æ2%) and HBA1/2 (a-thalassaemia; 17Æ0%) were similar to
the frequencies in 57 controls from the background population
(data not shown). Seventy-nine (30%) of the Hb SS patients
had a thalassaemia, 72 with single HBA1/2 deletion and seven
with double HBA1/2 deletions.
Haemoglobin concentration and haemolytic component
according to G6PD alleles
G6PD genotype and phenotype correlations are summarized in
Table I. Nineteen (13Æ8%) of the 138 male Hb SS patients were
hemizygous for both mutant alleles, i.e. had G6PD202A,376G
(G6PD A)). Twenty-seven (19Æ6%) were hemizygous for
G6PD376G but not G6PD202A, i.e. had G6PD202G,376G (G6PD
A). Ninety-two (66Æ7%) had neither the G6PD376G nor the
G6PD202A mutations, i.e. had G6PD202G,376A (G6PD B). Table II
shows that hemizygotes for both G6PD376G and G6PD202A had
lower haemoglobin concentration but not higher haemolytic
component than the G6PD B normal (G6PD202G,376A) partici-
pants. In contrast, the males with G6PD A (hemizygotes for
G6PD376G but not G6PD202A) did not have either significantly
lower haemoglobin concentration or higher haemolytic com-
ponent compared to the G6PD B group. In further analyses, the
males with G6PD202A,376G were compared to the combined
group of males with the other two genotypes.
Four (3Æ3%) of the 123 female Hb SS patients were homozyg-
otes for both the G6PD376G and G6PD202A alleles, i.e. had
G6PD202A,376G/202A,376G (G6PD A)). Twelve (9Æ8%) had
G6PD376G together with G6PD202A on one allele but not the
other, i.e. had G6PD202A,376G/202G,376A or G6PD202A,376G/202G,376G.
Fifty-six (45Æ5%) had G6PD376G on at least one allele but not in
combination with G6PD202A, i.e. had G6PD202G,376A/202G,376G or
G6PD202G,376G/202G,376G. Fifty-one (41Æ5%) had G6PD202G,376A/
202G,376A (G6PD B). Table III shows that the small number of
females with G6PD202A,376G/202A,376G (G6PD A)) had a trend to
lower haemoglobin concentrations but not higher haemolytic
component compared to those who were homozygotes for both
the G6PD376A and G6PD202G alleles (G6PD B). In contrast, the
participants with other combinations of mutant alleles did not
have lower haemoglobin concentrations compared to the G6PD
B group. Therefore, in further analyses, females who were not
homozygotes for both the G6PD376G and G6PD202A alleles were
combined into one group for comparison.
Clinical and laboratory variables according to presence
or absence of G6PD202A,376G (G6PD A)) in males and
females combined
Clinical characteristics according to G6PD202A,376G category are
summarized in Table IV for all 261 participants. Neither
a-thalassaemia genotypes nor Hb F levels varied significantly
according to G6PD202A,376G status. Similar results were obtained
in analyses restricted to 138 males (data not shown).
Associations of G6PD202A,376G (G6PD A)) with
haemoglobin concentration and markers of haemolysis
In unadjusted analysis, G6PD202A,376G was associated with a
lower haemoglobin concentration of 10 g/l on average
(P = 0Æ008) but not with higher values for the haemolytic
component (P = 0Æ6) (Table IV). In multiple linear regression
analysis that adjusted for degree of haemolysis, hydroxycarba-
mide treatment and recent blood transfusion, the association of
G6PD202A,376G with lower haemoglobin concentration persisted
(Fig 1). There was still no association of G6PD202A,376G with
higher haemolytic component after adjusting for a-thalassaemia
Table II. Haemoglobin concentration and haemolytic component by different G6PD202,376 genotypes in males. Results are given as mean (standard
error).
G6PD202G,376A
(G6PD B) N = 92
G6PD202G,376G
(G6PD A) N = 27
G6PD202A,376G
(G6PD A)) N = 19
Haemoglobin concentration (g/l), unadjusted 87 (1Æ5)1 84 (2Æ5) 79 (2Æ9)2
P* 0Æ3 0Æ022
Haemoglobin concentration (g/l), adjusted** 88 (1Æ4)1 84 (2Æ4) 77 (3Æ0)2
P* 0Æ1 0Æ001
Haemolytic component (relative unit), unadjusted 3Æ1 (0Æ1)3 3Æ3 (0Æ2)4 3Æ3 (0Æ2)5
P* 0Æ5 0Æ4
Haemolytic component (relative unit), adjusted*** 3Æ1 (0Æ1)3 3Æ3 (0Æ2)4 3Æ4 (0Æ3)5
P* 0Æ5 0Æ3
*Comparison with the G6PD202G,376A (G6PD B) group.
**Adjusted for recent blood transfusion and haemolytic component.
***Adjusted for hydroxycarbamide treatment and a-thalassaemia.
N: the number with the genotype in the data set. 1N=86, 2N=18, 3N=80, 4N=25, 5N = 17.
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and hydroxycarbamide therapy (P = 0Æ7) (Fig 2). Similar anal-
yses for the measurements from which the haemolytic compo-
nent was derived revealed confirmatory findings: LDH
(P = 0Æ6), AST (P = 0Æ9), total bilirubin (P = 0Æ09) and retic-
ulocyte count (P = 0Æ6) were not significantly increased in
individuals with G6PD202A,376G (Fig 2).
Associations of a-thalassaemia with haemoglobin
concentration and the haemolytic component
For comparison, we examined a-thalassaemia, a genetic
variation that is known to influence haemoglobin concentra-
tion, haemolysis and clinical course in sickle cell anaemia
(Embury et al, 1982; Higgs et al, 1982; Billett et al, 1986; Gill
et al, 1995; Guasch et al, 1999; Mouele et al, 2000; Chaar et al,
2006; Taylor et al, 2008). In unadjusted analyses, single and
double HBA1/2 deletions were associated with progressively
higher haemoglobin concentrations (P = 0Æ005), and these
increases in haemoglobin concentration were paralleled by
progressively decreasing values for the haemolytic component
(P = 0Æ007). Single HBA1/2 deletion was associated with a 4 g/l
increase in haemoglobin concentration and double HBA1/2
deletion with a 10 g/l increase. In multiple linear regression
analysis that adjusted for the significant covariates of trans-
fusion in past 2 months and white blood cell count, the
association of HBA1/2 deletions with higher haemoglobin
concentrations persisted. After adjustment for these covariates,
single HBA1/2 deletion was associated with an estimated 4 g/l
increase in haemoglobin concentration and double HBA1/2
deletion with a 6 g/l increase (P for trend = 0Æ012). Similarly,
in multiple regression analysis that adjusted for hydroxycar-
bamide therapy, the association of HBA1/2 deletions with
lower values for the haemolytic component persisted (P for
trend = 0Æ005). Children with a-thalassaemia more commonly
had a history of severe pain episodes in the past year compared
to children without a-thalassaemia (46% vs. 23%, P < 0Æ001).
Sub-group of patients not receiving hydroxycarbamide
Among 83 patients not receiving hydroxycarbamide treatment
and with no recent blood transfusion, the haemoglobin
concentration was lower in participants with G6PD202A,376G
(G6PD A)) than the other children in unadjusted analysis
(means of 64 vs. 81 g/l respectively; P = 0Æ0005) and after
adjusting for a-thalassaemia and the haemolytic component
(P < 0Æ0001). Neither the markers of haemolysis nor the
haemolytic component were significantly higher in the
G6PD202A,376G participants in this subgroup either in unad-
justed or adjusted analysis. In this same subgroup, single and
double deletion forms of a-thalassaemia were associated with
higher haemoglobin concentrations and lower values for the
haemolytic component (P for trend <0Æ001).
Discussion
The present findings suggest that G6PD202A,376G (G6PD A)), as
determined by molecular genetic testing, contributes to the
degree of anaemia in children and adolescents with sickle cell
anaemia by a mechanism that may not include increased
haemolysis. Our observation of a reduction in haemoglobin
concentration with G6PD202A,376G applied to sickle cell disease
children at steady state and was present either in unadjusted
analysis or after adjustment for the degree of haemolysis and
other important covariates. Likewise, the lack of an association
Table III. Haemoglobin concentration and haemolytic component by different G6PD202,376 genotypes in females. Results are given as mean (SE).
G6PD202G,376A/202G,376A








(G6PD A)) N = 4
Haemoglobin concentration
(g/l), unadjusted
86 (2Æ0)1 87 (1Æ5)2 89 (3Æ2) 80 (11Æ3)
P* 0Æ9 0Æ7 0Æ3
Haemoglobin concentration
(g/l), adjusted**
87 (1Æ7)1 88 (1Æ7)2 89 (3Æ6) 77 (5Æ4)
P* 0Æ8 0Æ7 0Æ06
Haemolytic component
(relative unit), unadjusted
2Æ9 (0Æ2)3 2Æ9 (0Æ1)4 2Æ8 (0Æ2) 2Æ3 (0Æ6)
P* 0Æ9 0Æ6 0Æ2
Haemolytic component
(relative unit), adjusted***
2Æ9 (0Æ1)3 2Æ9 (0Æ1)4 2Æ8 (0Æ3) 2Æ1 (0Æ4)
P* 0Æ9 0Æ8 0Æ1
*Comparison with the G6PD202G,376A/202G,376A (G6PD B) group.
**Adjusted for recent blood transfusion and haemolytic component.
***Adjusted for hydroxycarbamide treatment and a-thalassaemia.
1N=48, 2N=53, 3N=44, 4N=51.
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of G6PD202A,376G with haemolysis was observed either in
unadjusted analysis or after adjustment for a-thalassaemia,
hydroxycarbamide therapy and Hb F.
Most previous studies reported that G6PD A) does not
worsen anaemia or increase haemolysis in sickle cell disease
(Gibbs et al, 1980; Steinberg et al, 1988; Bernaudin et al, 2008),
although occasionally small series have reported a lower
haemoglobin concentration with this phenotype (Bouanga et al,
1998). Our present finding that G6PD202A,376G is not associated
with increased markers of haemolysis is thus consistent with
previous large studies conducted in children (Bernaudin et al,
2008) or in children and adults (Gibbs et al, 1980; Steinberg
et al, 1988) with sickle cell anaemia, but the association with
lower haemoglobin levels differs from these studies. For
instance, the study of Steinberg et al (1988) in children and
adults reported that haemoglobin concentrations averaged
4–5 g/l lower with G6PD A) compared to G6PD A+ and
G6PD B, but this difference was not statistically significant in
multivariate analysis (Steinberg et al, 1988). Bernaudin et al
(2008), a study in children, reported that the haemoglobin
concentration averaged 4 g/l higher with G6PD deficiency, even
though G6PD deficiency was significantly associated with
increased trans-cranial Doppler velocity, which was linked to
Table IV. Clinical and laboratory variables in children and adolescents with sickle cell anaemia based on G6PD status. Results are median (inter-








Age (years) 238 12 (7–16) 23 12 (9–16) 0Æ5
Female, N (%) 238 119 (50%) 23 4* (17%) 0Æ003
Medical history
Hydroxycarbamide treatment, N (%) 234 94 (40%) 23 11 (48%) 0Æ5
History of chronic transfusion program, N (%) 231 40 (17%) 23 4 (17%) 0Æ9
>10 units blood transfused life-time, N (%) 228 53 (23%) 23 10 (43%) 0Æ033
Blood transfusion
Past 1 month 58 29 (50%) 6 3 (50%) 0Æ3
Past 2 months 16 (28%) 3 (50%)
Past 3 months 13 (22%) 0
Two or more severe pain episodes in last 12 months, N (%) 238 73 (31%) 23 6 (26%) 0Æ6
Acute chest syndrome history 234 73 (31%) 23 11 (48%) 0Æ11
History of stroke, N (%) 234 28 (12%) 23 5 (22%) 0Æ18
Laboratory variables
a-thalassaemia, N (%) 232 21 0Æ4
Single deletion HBA1/2 68 (29%) 4 (19%)
Double deletion HBA1/2 7 (3%) 0 (0%)
Haemoglobin F (%) 123 12 (7–17) 11 7 (3–20) 0Æ3
Haemoglobin (g/l) 226 86 (77–96) 22 76 (65–90) 0Æ008
Mean cell volume (fl) 225 86 (81–93) 22 88 (81–91) 0Æ3
White blood cells (109/l) 225 11Æ5 (8Æ6–13Æ7) 22 10Æ7 (7Æ7–13Æ0) 0Æ6
Erythropoietin (iu/l) 232 70 (46–108) 23 85 (39–140) 0Æ5
Reticulocyte count (·109/l) 223 256 (188–351) 21 238 (220–309) 0Æ3
Aspatate aminotransferase (u/l) 227 45 (33–57) 22 48 (34–60) 0Æ8
Total bilirubin (lmol/l) 227 42Æ8 (30Æ8–63Æ3) 22 54Æ7 (37Æ6–90Æ6) 0Æ14
Lactate dehydrogenase (u/l) 218 458 (341–576) 22 432 (315–571) 0Æ6
Haemolytic component (relative unit) 212 3Æ1 (2Æ3–3Æ7) 21 3Æ2 (2Æ7–3Æ6) 0Æ6
Tricuspid regurgitation velocity (m/s) 219 2Æ4 (2Æ2–2Æ5) 19 2Æ3 (2Æ2–2Æ5) 0Æ7
















Fig 1. Estimated mean (standard error) haemoglobin concentration
in sickle cell anaemia by G6PD202A,376G status. From anova model
with adjustment for degree of haemolysis, recent blood transfusion
and hydroxycarbamide therapy.
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more severe anaemia (Bernaudin et al, 2008). An important
difference from these previous studies is that we examined a
single G6PD deficiency genotype, G6PD202A,376G, rather than the
G6PD A) phenotype determined enzymatically, which may
include a variety of genotypes in addition to G6PD202A,376G, such
as G6PD376G,968C. Also, enzymatic determination of G6PD may
have decreased accuracy in hyperhaemolytic states because of
higher enzyme concentrations in younger erythrocytes (Beutler
et al, 1954; Marks et al, 1958). The facts that we studied the
PUSH cohort in a prospective, cross-sectional manner with
strictly defined steady state and that we performed G6PD
genotyping by molecular genetic testing instead of electropho-
resis or enzyme activity may help to explain the variance in the
findings with previous studies (Steinberg et al, 1988; Bernaudin
et al, 2008) and increase confidence in the present finding of
lower haemoglobin concentration with G6PD202A,376G. Further-
more, we performed molecular genetic testing for a-thalassmia
in parallel to testing for G6PD202A,376G and observed higher
haemoglobin concentrations, less haemolysis and more frequent
pain crises with HBA1/2 deletions. These findings with regard to
a-thalassaemia are consistent with the observations of many
other investigators (Embury et al, 1982; Higgs et al, 1982; Billett
et al, 1986; Gill et al, 1995; Guasch et al, 1999; Mouele et al,
2000; Chaar et al, 2006; Taylor et al, 2008).
There are a number of limitations to our present study. The
results are based on a single, cross-sectional analysis rather than
on repeated determinations and there was small sample size in
the G6PD202A,376G group. Furthermore, we did not perform
molecular genetic testing for all of the mutations that could
contribute to the G6PD A) phenotype, and we could not rule
out G6PD968C in alleles classified as G6PD A in this study.
Given that the haemoglobin concentration was decreased
without an apparent increase in haemolysis, our findings raise
the possibility that G6PD202A,376G in sickle cell anaemia might
be associated with decreased production of erythrocytes. Of
note is a study indicating that G6PD plays an important role
in erythroid maturation. With complete G6PD deficiency,
erythroid precursors are unable to cope with high concentra-
tions of oxygen radicals as haemoglobin synthesis is initiated,
and they die by apoptosis (Paglialunga et al, 2004).
These results may not be relevant for patients with relatively
mild G6PD deficiency associated with G6PD202A,376G. On the
other hand, it is conceivable that any slight tendency to
increased apoptosis of G6PD202A,376G erythroid precursors at a
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(E) Reticulocyte count (109/l)
P = 0·6
(A) Haemolytic component (relative unit)
Fig 2. Estimated mean (standard error) haemolytic component, lactate dehydrogense, aspartate aminotransferase, total bilirubin, and reticulocyte
count in sickle cell anaemia by G6PD status. From anova model with adjustment for hydroxycarbamide treatment and a-thalasssaemia.
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minimally haemoglobinized stage might become more man-
ifest in the setting of the markedly increased erythropoiesis
and hypoxic conditions (low haemoglobin concentration and
lower haemoglobin oxygen saturation) of sickle cell anaemia
(Qian et al, 2001; Aispuru et al, 2008). Thus, based on our
findings, studies of apoptotic markers in early G6PD A) ery-
throid progenitors exposed to varying degrees of oxidant stress
and hypoxia may be of interest. Furthermore, elucidation of
the precise pathogenesis of increased anaemia in G6PD-
deficient sickle cell anaemia patients may help identify new
disease pathways amenable to eventual treatment interven-
tions.
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